Stereotactic single-dose radiotherapy of lung metastases
Stereotactic single-dose radiotherapy of lung metastases
复制标题
DOI：
10.1007/s00066-007-1724-z
复制
发表时间：
2007-12-01
影响因子：
3.1
通讯作者：
Herfarth, Klaus
中科院分区：
文献类型：
--
作者：
Hof, Holger;Hoess, Angelika;Herfarth, Klaus
背景资料：立体定向治疗方法导致照射量的显着减少，这应该使肺靶点更容易接受radiotherapy.Patients和方法：1997年5月至2005年12月，61例患者接受立体定向单剂量剂量治疗71肺转移瘤。等中心剂量范围为12至30戈伊。生存率和局部肿瘤控制率进行了评估prospectively.Results：经过中位随访期14个月的精算总生存率分别为78.4%，65.1%，47.8%，12，24和36个月后治疗，分别。随访期间未发生进一步转移的患者生存率显著更高（p = 0.023）。治疗后12、24和36个月的精算局部无进展率分别为88.6%、73.7%和63.1%。虽然大多数患者（70.4%）的病灶周围正常组织的变化，这些都不相关的临床相关toxics.Conclusion：立体定向单剂量放射治疗是一种可行的，安全有效的局部治疗选择孤立性肺转移瘤的禁忌症，手术或缓解症状性肺转移瘤。
Background: Stereotactic treatment approaches lead to a significant reduction of irradiated volumes, which should make pulmonary targets more accessible to radiotherapy.Patients and Methods: Between May 1997 and December 2005, 61 patients received stereotactic single-dose dose treatment for 71 pulmonary metastases. Doses to the isocenter ranged from 12 to 30 Gy. Survival and local tumor control rates were evaluated prospectively.Results: After a median follow-up period of 14 months the actuarial overall survival was 78.4%, 65.1%, and 47.8% 12, 24, and 36 months after therapy, respectively. There was a significantly better survival (p = 0.023) for patients not developing further metastases during follow-up. The actuarial local progression-free rate was 88.6%, 73.7%, and 63.1% 12, 24, and 36 months after therapy. Although the majority of patients (70.4%) developed perifocal normal-tissue changes, these were not related to clinically relevant toxicities.Conclusion: Stereotactic single-dose radiotherapy is a feasible, safe and effective local treatment option for solitary pulmonary metastases in patients with contraindications to surgery or for palliation of symptomatic pulmonary metastases.